Evo Fund reduced its stake in Modalis Therapeutics Corporation to 7.61% and filed a 5% Rule Report. The report was filed on 22 October 2026 following the reduction in its holding.
Evo Fund filed a change report, also known as a 5% Rule Report, with the regional finance bureau on 22 October 2026 concerning its holding in Modalis Therapeutics Corporation, which is listed on the TSE Growth market. The filing was prompted by a reduction of at least 1 percentage point in its shareholding ratio and in its standalone shareholding ratio.
According to the report, Evo Fund's holding in Modalis Therapeutics Corporation fell to 7.61%, down 1.35 percentage points from the previous report. The date on which the reduction in the shareholding ratio was confirmed was 15 October 2026.
The filing falls under the disclosure requirements for the acquisition and holding of shares, indicating that the reduction triggered the obligation to file a change report under the 5% Rule.